Home Newsfeeds On CNBC: Leon Cooperman Says Energy Stocks Still Seem Cheap

On CNBC: Leon Cooperman Says Energy Stocks Still Seem Cheap

-CNBC Interview

byBenzinga Newsdesk

November 1, 2022

1 minute read

-CNBC Interview

S&P 500 Records Weekly Gain, Market Volatility Increases

By Lisa Levin

March 27, 6:05 AM

The S&P 500 settled the volatile session on a higher note amid recent concerns over the stability of the banking industry. Deutsche Bank AG (NYSE: DB) shares fell over 3% on Friday after the price of the bank's credit default swaps increased, raising concerns about the bank's health.

AAPL

Walmart’s Newly Remodeled Store Format Could Increase Customer Spend, Says Analyst

By Nabaparna Bhattacharya

April 14, 2:45 PM

Telsey Advisory Group analyst Joseph Feldman reiterated an Outperform rating on the shares of Walmart Inc. (NYSE:WMT) with a price target of…

WMT

BMO Capital Maintains Market Perform on Steel Dynamics, Raises Price Target to $100

By Benzinga Newsdesk

November 14, 9:20 AM

BMO Capital analyst David Gagliano maintains Steel Dynamics (NASDAQ:STLD) with a Market Perform and raises the price target from $89 to $100.

STLD

Arcutis Biotherapeutics Says STRATUM Study Met Its Primary Endpoint, With Nearly 80% Of ZORYVE Foam Treated Individuals Reaching Investigator Global Assessment; Also Demonstrated Improvement On All Secondary Endpoints, Including Itch, Scaling And Eryth…

By Benzinga Newsdesk

December 16, 7:57 PM

ZORYVE Foam Clinical DataThe approval is supported by positive results from Arcutis' Phase 2 and pivotal Phase 3 trials in seborrheic dermatitis. The STudy of Roflumilast

ARQT

On CNBC: Leon Cooperman Says Energy Stocks Still Seem Cheap

Related Posts

S&P 500 Records Weekly Gain, Market Volatility Increases

Walmart’s Newly Remodeled Store Format Could Increase Customer Spend, Says Analyst

BMO Capital Maintains Market Perform on Steel Dynamics, Raises Price Target to $100

Arcutis Biotherapeutics Says STRATUM Study Met Its Primary Endpoint, With Nearly 80% Of ZORYVE Foam Treated Individuals Reaching Investigator Global Assessment; Also Demonstrated Improvement On All Secondary Endpoints, Including Itch, Scaling And Eryth…